Market Overview

UPDATE: Piper Jaffray Downgrades Biogen Idec to Neutral on Valuation

Share:
Related BIIB
The Catalysts Biogen Idec Investors Should Watch
Evercore ISI Technical Analysis: The 'Single Best Idea'
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline (Seeking Alpha)

Piper Jaffray reduced its rating on Biogen Idec (NASDAQ: BIIB) from Overweight to Neutral and lowered its price target from $175 to $166.

Piper Jaffray commented, "We are downgrading BIIB to Neutral from Overweight based on valuation as we believe expectations are high for the upcoming BG-12 launch and fairly reflected in shares given its premium P/E multiple (21x 2013) versus the large cap group average (16x). We believe this level of premium will be difficult to maintain unless Phase III dexpramipexole ALS data (early 2013) supports regulatory approval. As a result, we are reducing our price target to $166 from $175 as we assume a lower multiple (18x vs. 19x previously) on our 2014 EPS estimates."

Biogen Idec closed at $150.00 on Wednesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Feb 2015Leerink SwannMaintainsOutperform
Jan 2015CitigroupMaintainsBuy
Jan 2015BarclaysMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (BIIB)

Around the Web, We're Loving...